The Company is pleased to announce its prototype diagnostic test for oesophageal adenocarcinoma has shown strong diagnostic performance detecting up to 90% of people with the frequently fatal condition. The results were presented overnight at the 18th World Congress for Esophageal Diseases being held virtually, and in Tokyo, Japan 26-28 September 2022.
The Oesophageal Cancer Diagnostic is Proteomics International’s latest test from the Company’s Promarker™ Pipeline. The results build on a successful collaboration with the QIMR Berghofer Medical Research Institute [ASX: 4 February 2022] which validated a select panel of biomarkers in a study of more than 300 patients across two independent clinical cohorts. Proteomics International owns the exclusive worldwide rights to commercialise the biomarkers, which are patented in multiple jurisdictions [ASX: 21 June 2022].
